Recombinant Human GM2A Protein，His

GM2A (GM2 ganglioside activator protein) is a vital protein involved in the metabolism of gangliosides, complex glycosphingolipids that play essential roles in cell signaling and neuronal function. Mutations in the GM2A gene lead to GM2 gangliosidosis, a group of lysosomal storage disorders, including the Tay-Sachs and Sandhoff diseases. These conditions result in the accumulation of GM2 gangliosides, causing severe neurological deficits and ultimately leading to premature death. The study of GM2A recombinant proteins has gained significant attention in the fields of molecular biology and medicine, as it offers insights into the biochemical pathways associated with ganglioside metabolism. Research on GM2A involves delineating its structure, function, and interactions with other proteins and lipids, which could pave the way for developing therapeutic strategies aimed at mitigating the effects of GM2 gangliosidosis. Additionally, the recombinant production of GM2A enables the exploration of its functional properties in vitro and the potential for enzyme replacement therapies. Understanding the mechanisms behind GM2A's activity and the pathological consequences of its deficiency can provide crucial information for developing targeted interventions for those affected by related disorders. Consequently, GM2A research represents a promising avenue for advancing our knowledge of neurodegenerative diseases and exploring potential treatment modalities.